The following article features coverage from the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Anaheim, California. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Two single-nucleotide polymorphisms (SNPs) are associated with progression-free survival (PFS) among patients with diffuse large B cell lymphoma (DLBCL) receiving R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone], according to a poster presented at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference.1

For this retrospective study, researchers analyzed DNA samples from 166 patients with newly diagnosed DLBCL treated with R-CHOP to determine whether any of 11 SNPs was associated with a response to treatment.

Mean PFS was 957 days. Two SNPS (rs4880 and rs1870377) had an association with PFS: the CC mutation of rs4880 was linked to worse PFS, possibly due to increased resistance to cyclophosphamide and doxorubicin, and the AA allele of rs1870377 was linked to better PFS.

RELATED: Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

The researchers concluded that while an association was found between PFS and these SNPs, further study is needed for confirmation.

Read more of Cancer Therapy Advisor‘s coverage of the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference by visiting the conference page.

Reference

  1. Zheng K, Hu Y, New-aaron M, Yee GC, Meza JL. Pharmacogenomics of R-CHOP in patients with diffuse large B-cell lymphoma. Poster presented at: 13th Hematology/Oncology Pharmacy Association Annual Conference; March 29-April 1, 2017; Anaheim, CA.